Global Information
회사소개 | 문의 | 비교리스트

특발성 폐섬유화증 : 파이프라인 리뷰

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232804
페이지 정보 영문 503 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


특발성 폐섬유화증 : 파이프라인 리뷰 Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 503 Pages

특발성 폐섬유화증(IPF)은 폐의 고립성 진행성 질환입니다. 마른기침, 호흡 곤란(특히 운동중/운동후), 지속적인 피로, 체중 감소 등의 증상을 볼 수 있습니다. 치료에는 항산화제, 생물학적 반응 수식 물질, 항섬유화제, 항응고제 등이 포함됩니다.

특발성 폐섬유화증 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

특발성 폐섬유화증 - 개요

특발성 폐섬유화증 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

특발성 폐섬유화증 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

특발성 폐섬유화증 치료제 개발에 참여하고 있는 기업

  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • Asahi Kasei Pharma Corp
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • BLR Bio LLC
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • GNI Group Ltd
  • Histocell SL
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • MorphoSys AG
  • Nuevolution AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Sanofi
  • Sorrento Therapeutics Inc
  • SPR Biosciences LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Yuhan Corp

약제 개요

특발성 폐섬유화증 - 휴지중인 프로젝트

특발성 폐섬유화증 - 개발이 중지된 제품

특발성 폐섬유화증 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences*Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020

List of Figures

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Idiopathic Pulmonary Fibrosis - Overview
  • Idiopathic Pulmonary Fibrosis - Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q